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Background
Modified vaccinia virus Ankara (MVA) vectored vaccines
have been intensively investigated in several studies. In a
therapeutic vaccination trial, we demonstrated that MVA
expressing the HIV-1 protein Nef (MVA-nef) was safe in
10 HIV-1 infected individuals under ART and immuno-
genic in regard to the elicitation of IFN-γ mediated CD4 T-
cell responses. Recent advancements in polychromatic
flow-cytometry technology revealed that the sole evalua-
tion of IFN-γ provides limited information about the
quality of the immune response. In fact, simultaneous
production of multiple cytokines by T-cells and a high
proliferative capacity are associated with superior control
of viral replication.
Methods
In a retrospective setting, we simultaneously assessed the
expression of IFN-γ, IL-2, MIP-1β, CD154 and CD45RA in
Nef-specific T-cell populations throughout the vaccina-
tion trial. Furthermore we applied a multi-colour CFSE
based proliferation assay investigating the proliferative
capacity and the simultaneous expression of IFN-γ, IL-2
and MIP-1β.
Results
Following MVA-nef vaccination, we observed a significant
increase of polyfunctional Nef-specific CD4 T-cells, simul-
taneously expressing IFN-γ, IL-2 and CD154. Using the
standard ICS no increase of Nef-specific CD8 T-cell
responses was detected. However, by the CFSE based pro-
liferation assay, we observed a clear expansion and a gen-
erally enhanced proliferative capacity of Nef-specific CD8
T-cells. Notably, MVA-nef induced increased IL-2 produc-
tion by Nef-specific CD4 T-cells correlated with MVA-nef
induced increased proliferative capacity of Nef-specific
CD8 T-cells suggesting the possibility of a causal link
between the two functions.
Conclusion
These results hold promise for the use of the poxvirus
derived MVA-vector to stimulate potentially effective anti
HIV T-cell responses and highlight the importance of
sophisticated immunomonitoring tools to unravel con-
cealed effects of immunologic interventions.
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